1. Home
  2. SAGE vs NML Comparison

SAGE vs NML Comparison

Compare SAGE & NML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • NML
  • Stock Information
  • Founded
  • SAGE 2010
  • NML 2012
  • Country
  • SAGE United States
  • NML United States
  • Employees
  • SAGE N/A
  • NML N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • NML Finance/Investors Services
  • Sector
  • SAGE Health Care
  • NML Finance
  • Exchange
  • SAGE Nasdaq
  • NML Nasdaq
  • Market Cap
  • SAGE 474.6M
  • NML 517.3M
  • IPO Year
  • SAGE 2014
  • NML N/A
  • Fundamental
  • Price
  • SAGE $7.77
  • NML $9.20
  • Analyst Decision
  • SAGE Hold
  • NML
  • Analyst Count
  • SAGE 19
  • NML 0
  • Target Price
  • SAGE $9.88
  • NML N/A
  • AVG Volume (30 Days)
  • SAGE 1.2M
  • NML 219.3K
  • Earning Date
  • SAGE 04-24-2025
  • NML 01-01-0001
  • Dividend Yield
  • SAGE N/A
  • NML 9.75%
  • EPS Growth
  • SAGE N/A
  • NML N/A
  • EPS
  • SAGE N/A
  • NML N/A
  • Revenue
  • SAGE $41,243,000.00
  • NML N/A
  • Revenue This Year
  • SAGE $100.39
  • NML N/A
  • Revenue Next Year
  • SAGE $70.86
  • NML N/A
  • P/E Ratio
  • SAGE N/A
  • NML N/A
  • Revenue Growth
  • SAGE N/A
  • NML N/A
  • 52 Week Low
  • SAGE $4.62
  • NML $6.09
  • 52 Week High
  • SAGE $17.51
  • NML $7.33
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 48.49
  • NML 62.43
  • Support Level
  • SAGE $7.99
  • NML $8.94
  • Resistance Level
  • SAGE $8.81
  • NML $9.10
  • Average True Range (ATR)
  • SAGE 0.31
  • NML 0.16
  • MACD
  • SAGE -0.06
  • NML 0.03
  • Stochastic Oscillator
  • SAGE 9.57
  • NML 93.76

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.

Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States.

Share on Social Networks: